Medical devices, healthcare technology and the business of care
510(k) clearance · K262442

HipStudio Analysis

Replasia BV · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONK262442

What did the FDA decide?

FDA recorded a substantial equivalence decision dated September 22, 2026 for HipStudio Analysis, a Class II Medical Image Management and Processing System under 21 CFR 892.2050, product code LLZ, submitted by Replasia BV of Leuven, Belgium. The submission, K262442, was dated and received July 20, 2026. The 510(k) summary identifies the development name HipStudio Simulation Service and states the device will be marketed as HipStudio Analysis; the predicate cited is the Forward 3D Motion Simulation Service (Zimmer Biomet, K162559), with HipCheck (Stryker, K230045) listed as a reference device.

The described service processes uploaded hip CT data into three-dimensional anatomy models, then runs motion simulations and calculates morphological parameters, with the resulting report delivered to trained radiologists and orthopedic surgeons; clinicians do not operate the analysis software directly. The summary states the service supports but does not replace clinical judgment. The decision letter does not set out patient-selection thresholds, imaging protocols or treatment instructions, and the source does not report performance testing results or the basis for the equivalence finding, so those remain unknown from this material.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Sep 22, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262442
Regulatory pathway
510(k) premarket notification
Applicant
Replasia BV
Product code
LLZ
Decision code
SESE
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Image Processing, Radiological.

Applicant
Replasia BV
Product code
LLZ
FDA device class
2

FDA decision timeline

  1. K262442 received

    Application receipt date recorded by FDA.

  2. K262442 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LLZ

Product / regulatory recordCompanyPathwayDecision dateSource
The Jacobs Institute510(k) clearanceNov 5, 2026FDA
Elevate Imaging, Inc.510(k) clearanceNov 4, 2026FDA
Canon Medical Informatics, Inc.510(k) clearanceOct 29, 2026FDA
Mim Software, Inc.510(k) clearanceOct 26, 2026FDA
Perception Vision Medical Technology Co., Ltd.510(k) clearanceOct 21, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Replasia BV

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Leuven

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records